- Home
- JAGU vs EVAX Comparison
JAGU vs EVAX Comparison
Compare JAGU & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAGU | EVAX |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | Canada | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 25.5M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JAGU | EVAX |
|---|---|---|
| Price | $1.03 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 176.9K | 58.0K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $2.72 |
| 52 Week High | $3.60 | $6.92 |
Technical Indicators
Market Signals| Indicator | JAGU | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 62.73 |
| Support Level | N/A | $3.35 |
| Resistance Level | $1.76 | $3.62 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 4.90 | 79.55 |
Price Performance
Historical ComparisonAbout JAGU Jaguar Uranium Corp. Class A Common Shares
Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.